XBiotech公司已正式启动一项II期临床试验,旨在评估其候选药物Vilamakitug用于治疗活动性中轴型脊柱关节炎的疗效与安全性。该试验的启动标志着公司在探索炎症性疾病新疗法方面迈出了重要一步。
XBiotech公司已正式启动一项II期临床试验,旨在评估其候选药物Vilamakitug用于治疗活动性中轴型脊柱关节炎的疗效与安全性。该试验的启动标志着公司在探索炎症性疾病新疗法方面迈出了重要一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.